reports
Editas Medicine Announces First Quarter 2024 Results Conference Call a...
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call begins.Participants should ask to be c...
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Coll...
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimm...
Editas Medicine to Present Pre-clinical Data Demonstrating Progression...
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to ...
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results an...
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational runway expected into 2026 CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- E...
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Co...
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call...
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Guggenheim 6th Annual Biotechnology ConferenceFormat: Fireside ChatDate: Wednesday, February 7Time: 9:30 a.m. ETLocation: New York, NY Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Fireside ChatDate: Tuesday, Feb...
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic P...
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue to sublicense foundational IP Strong financial position with operational runway into 2026 Company to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PST CAMBRIDGE, Mass., Jan. 08, 2...
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare C...
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the websi...
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive Li...
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene edit...
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 ...
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant E...
- Dave Nicoski
- Ross LaDuke
RGLD ROYAL GOLD INC
DPZ DOMINO'S PIZZA INC.
TRIP TRIPADVISOR INC.
PODD INSULET CORPORATION
PENN PENN NATIONAL GAMING INC.
OMI OWENS & MINOR INC.
NG. NOVAGOLD RESOURCES INC.
MYGN MYRIAD GENETICS INC.
MNRO MONRO INC
M MACY'S INC
KHC KRAFT HEINZ COMPANY
GCO GENESCO INC.
EMN EASTMAN CHEMICAL COMPANY
EDIT EDITAS MEDICINE INC.
ANIK ANIKA THERAPEUTICS INC.
UFCS UNITED FIRE GROUP INC.
AXP 11 88 0 SOLUTIONS AG
UA AMERICAN EXPRESS COMPANY
TGT UNDER ARMOUR INC. CLASS C
ALCO TARGET CORPORATION
VMD ALICO INC.
PNTG VIEMED HEALTHCARE
TWST PENNANT GROUP
ALXO TWIST BIOSCIENCE
CG ALX ONCOLOGY HOLDINGS
CLSK CARLYLE GROUP INC
BEAM CLEANSPARK
XMTR BEAM THERAPEUTICS
VSCO XOMETRY INC
EMBC VICTORIA'S SECRET & CO
VH EMBECTA CORP
VASTRA HAMNEN CORPORATE FINANCE AB
Editas Medicine Announces Third Quarter 2023 Results and Business Upda...
Editas Medicine Announces Third Quarter 2023 Results and Business Updates Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar Granted Vor Bio a non-exclusive license for Cas9 patents for ex vivo HSC therapies for the treatment and prevention of hematological malignancies Strengthened Executive Team with appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer CAMBRIDGE, Mass., Nov. 03, 2023 ...
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Tri...
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the R...
Editas Medicine Announces Third Quarter 2023 Results Conference Call a...
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call begins.Participants should ask to...
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RM...
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). “Sickle cell disease is a devastating disease that leads to anemia, pain ...
Editas Medicine Reports Inducement Grants to New Chief Commercial and ...
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordance with ...
Editas Medicine Strengthens Executive Leadership Team with Appointment...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company’s current and future pipelin...
Editas Medicine Announces Upcoming Investor Events
Editas Medicine Announces Upcoming Investor Events CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 7Time: 3:00 p.m. ETLocation: Boston, MA Morgan Stanley 21st Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, September 11Time: 10:00 a.m. ETLocation: New York, NY Cantor Global Healthcare Conference 2023Form...
Editas Medicine Announces Second Quarter 2023 Results and Business Upd...
Editas Medicine Announces Second Quarter 2023 Results and Business Updates On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end Strengthened Executive Team with Appointments of Erick Lucera as Chief Financial Officer and Linda C. Burkly, Ph.D., as Chief Scientific Officer CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing ...
Editas Medicine and Azzur Group Expand Partnership to Accelerate Edita...
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.